Market closedADR
Inventiva/$IVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Ticker
$IVA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
123
Website
Inventiva Metrics
BasicAdvanced
$282M
-
-$3.33
0.72
-
Price and volume
Market cap
$282M
Beta
0.72
52-week high
$3.27
52-week low
$2.67
Financial strength
Interest coverage (TTM)
-1.13%
Management effectiveness
Valuation
Price to revenue (TTM)
11.035
Growth
Revenue change (TTM)
-36.43%
Earnings per share change (TTM)
26.56%
3-year revenue growth (CAGR)
20.09%
3-year earnings per share growth (CAGR)
34.47%
Inventiva News
AllArticlesVideos
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
GlobeNewsWire·9 hours ago
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript
Seeking Alpha·6 days ago
Inventiva reports its 2024 full year results and provides a business update
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Inventiva stock?
Inventiva (IVA) has a market cap of $282M as of April 02, 2025.
What is the P/E ratio for Inventiva stock?
The price to earnings (P/E) ratio for Inventiva (IVA) stock is 0 as of April 02, 2025.
Does Inventiva stock pay dividends?
No, Inventiva (IVA) stock does not pay dividends to its shareholders as of April 02, 2025.
When is the next Inventiva dividend payment date?
Inventiva (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva?
Inventiva (IVA) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.